A new medication for patients with mild to moderate Alzheimer’s disease – participants needed

Running across the Thames Valley, this study aims to test a new medication (MK8931) in patients with mild to moderate Alzheimer’s disease.

The medication acts to reduce the levels of a brain protein called amyloid, which is known to build up in excessive amounts in those with Alzheimer’s disease.

The study will also measure how well people are able to tolerate the medication, and monitors for any side effects.

Can I take part?

We are looking for people who meet the following criteria:

  • Aged 50-85
  • Have a diagnosis of Alzheimer’s disease
  • Be willing and able to have 6 brain scans during the study
  • If you take any medication for your memory, to have been on the same medication at the same dose for at least 3 months
  • Have a relative or friend able to come to the visits as a study partner
  • Be otherwise fit and well, with no major health issues
  • Be fluent in English, and to be able to see and hear well enough to complete questionnaires with research team

What will happen if I take part?

In this study people will be randomly allocated to taking the study medication or having a dummy drug (called a placebo). You have a 2 in 3 chance of being given the study medication. The medication is in tablet form and you will be asked to take this once a day.

To see if you are eligible to join the trial we will ask you to come for a screening visit. This visit involves memory assessment, physical health checks, a brain scan and an eye examination.

The study lasts for 80 weeks. During the study we ask you to come to the hospital every three months, with more frequent visits during the visit 4 weeks of the study. The appointments will include similar assessments to the screening visit.

Each visit will last between 1-4 hours, and you study partner should also attend with you.

Date required



Oxford Health NHS Foundation Trust


Ann Murphy
Oxford Health NHS Foundation Trust
01865 902694